Project Grant R03TR004687
Award Date
8/15/23
Completion Date
8/14/24
Dollars Obligated
$156K
Federal Agency
National Center for Advancing Translational Sciences
Federal Grant Program
93.350
Assistance Type
Project Grant
Place of Performance
Penn State University, PA 16802, USA
Similar Awards
The National Cancer Institute (NCI) awarded a $4,653,104 Cooperative Agreement (CFDA 93.395 - Cancer Treatment Research) to the Massachusetts Institute of Technology (MIT) on September 6, 2024. This funding supports a comprehensive, coordinated effort to discover and develop small molecule agents that can impact the PAX3-FOXO1 fusion oncoprotein, which drives the highly fatal fusion-positive alveolar rhabdomyosarcoma (FP-RMS) cancer. The project engages a multidisciplinary team of chemical...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $194,013 to Sanford Research to develop the first genetically engineered mouse models that faithfully replicate key features of human high-risk rhabdomyosarcoma (RMS), a prevalent soft tissue sarcoma in children with poor prognosis. The overarching objective is to identify therapeutic genetic factors and pathways that impede RMS progression, with a particular focus on exploring the...
The U.S. Department of Defense's Defense Health Agency awarded a $488,000 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to The Geneva Foundation, a non-profit organization. The grant, awarded on July 1, 2024, supports research to investigate novel mechanisms of regulating the PAX3-FOXO1 fusion oncogene in rhabdomyosarcoma, a type of soft tissue cancer. The research aims to advance treatments for this rare and aggressive form of cancer, with a projected...
This federal Project Grant award from the National Center for Advancing Translational Sciences (NCATS), CFDA 93.350, will fund research to develop a treatment for Familial Platelet Disorder with Myeloid Malignancy (FPDMM), a rare genetic disorder affecting hundreds of people in the U.S. The $489,500 award to The Children's Hospital of Philadelphia will support studies on the small compound Repsox, which has shown promise in correcting the platelet defects and reducing leukemia risk in FPDMM. The...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $658,223 to the University of Houston System to investigate the role of the TAK1 signaling protein in the development and growth of rhabdomyosarcoma (RMS), a type of cancerous sarcoma. The key objectives are to 1) examine the molecular mechanisms by which TAK1 drives RMS tumorigenesis and inhibits muscle cell differentiation, 2) investigate how TAK1 signaling impacts cancer stem cell...
The federal Project Grant award R01CA288967, with $452,549 in funding from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research program), supports research at Emory University to comprehensively characterize and target the intrinsic and extrinsic molecular features of MYC-driven osteosarcoma, the most common bone tumor in pediatric patients. The project aims to define the unique intrinsic and extrinsic molecular signatures of MYC-amplified osteosarcoma tumors, including their...
This $1,104,864 five-year federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to identify small molecule inhibitors that selectively bind the leucine zipper domain and disrupt the protein-protein interaction between the TFE3 chimeric proteins (TFE3-OS) and wild-type TFE3 (TFE3-WT). The key objectives are to optimize lead compounds like terfenaidine and fexofenadine, and screen for novel molecules that can inhibit TFE3 dimerization, with...
This $1,149,870 Cooperative Agreement award from the National Cancer Institute (NCI) under the 21st Century Cures Act - Beau Biden Cancer Moonshot program (CFDA 93.353) will establish a Pediatric Solid Tumor Microenvironment (PSTME) Atlas. The primary goal is to investigate the unique tumor microenvironments of prominent pediatric cancers like rhabdomyosarcoma, neuroblastoma, and Wilms tumors, with the aim of uncovering mechanisms of therapy resistance and identifying vulnerabilities for more...
The federal Cooperative Agreement award with ID UM1CA294119 was granted by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to The University of Texas Southwestern Medical Center for a project titled "Targeting Transcriptional Addiction in Fusion-Driven Sarcoma". The $2,203,647 award, with a performance period from July 8, 2024 to June 30, 2029, will fund research aimed at identifying and advancing small molecules that target transcriptional fusion...
This $483,760 Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research by The Trustees of the University of Pennsylvania to investigate the role of the DCAF15 protein in acute myeloid leukemia (AML). The key objectives are to: (A) determine the biological function of DCAF15 in myeloid development and leukemia in vivo, (B) examine the role of cohesin acetylation in AML pathogenesis, and (C) develop small molecule degraders targeting...